Vanda Pharmaceuticals Inc.  

(Public, NASDAQ:VNDA)   Watch this stock  
Find more results for Vanda Pharmaceuticals Inc
Aug 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 8.34 - 15.51
Open     -
Vol / Avg. 0.00/717,400.00
Mkt cap 504.47M
P/E 8.71
Div/yield     -
EPS 1.35
Shares 42.29M
Beta 1.87
Inst. own 107%
Oct 26, 2015
Q3 2015 Vanda Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Aug 12, 2015
Vanda Pharmaceuticals Inc at Canaccord Genuity Growth Conference
Jul 29, 2015
Q2 2015 Vanda Pharmaceuticals Inc Earnings Call - Webcast
Jul 29, 2015
Q2 2015 Vanda Pharmaceuticals Inc Earnings Release
Jun 23, 2015
Vanda Pharmaceuticals Inc at JMP Securities Life Sciences Conference - Webcast
Jun 18, 2015
Vanda Pharmaceuticals Inc Annual Shareholders Meeting
Jun 4, 2015
Vanda Pharmaceuticals Inc at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -19.53% 40.25%
Operating margin -19.79% 40.00%
EBITD margin - -109.20%
Return on average assets -9.88% 12.81%
Return on average equity -14.30% 19.70%
Employees 105 -
CDP Score - -


Suite 300E, 2200 Pennsylvania Ave NW
United States - Map
+1-202-7343400 (Phone)
+1-202-2961450 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company's product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. HETLIOZ (tasimelteon) is a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) for which a New Drug Application (NDA) was approved by the United States Food and Drug Administration (FDA). Fanapt (iloperidone) is a product for the treatment of schizophrenia. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is under clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Officers and directors

H. Thomas Watkins Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Mihael H. Polymeropoulos M.D. President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
James Patrick Kelly Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
Paolo Baroldi M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 64
Bio & Compensation  - Reuters
Thomas Edward Gibbs Senior Vice President, Chief Commercial Officer
Age: 43
Bio & Compensation  - Reuters
Michael F. Cola Independent Director
Age: 55
Bio & Compensation  - Reuters
Richard W. Dugan Independent Director
Age: 73
Bio & Compensation  - Reuters
Vincent J. Milano Independent Director
Age: 51
Bio & Compensation  - Reuters